India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE
American: IGC) announced that it is enrolling participants
suffering from mild to severe dementia due to Alzheimer’s disease
for its Phase 1 clinical trial.
Our subsidiary, IGC Pharma, LLC, received approval from an
Institutional Review Board (“IRB”) as previously disclosed, engaged
a Principal Investigator and a study site, and began enrolling
participants for a Phase 1 trial on its Investigational Drug
Candidate (“IDC”), IGC-AD1.
Our Phase 1 study is a placebo-controlled study. IGC-AD1 will be
administered for three 14-day periods, with the dose escalated in
each of the periods. The participants will be monitored daily,
certain data will be collected, and while collection of safety data
is the primary objective, we will, for research purposes, collect
data that extends beyond safety. For example, we expect to collect
data on how fast IGC-AD1 is absorbed through the body
(pharmacokinetics), how long it lasts in the body, and whether
different individuals process it differently based on polymorphisms
of the liver enzyme CYP450 2C9. In addition, we will monitor,
through tests, certain behavioral aspects brought on by dementia to
help us in anticipated future phases of the study.
As previously reported, on July 30, 2020, IGC received notice
from the U.S. Food and Drug Administration (“FDA”) to proceed with
a 12-subject Phase 1 human clinical trial (“removal of full
clinical hold”) on its Investigational New Drug Application
(“INDA”), IGC-AD1, submitted under Section 505(i) of the federal
Food, Drug, and Cosmetic Act.
To receive investigational drug approval as a pharmaceutical
drug, the Sponsor (IGC Pharma, LLC) must conduct several trials and
gather data. These typically start with pre-clinical trials that
involve testing the IDC on cells outside of a living organism (in
vitro), followed by animal testing. This in vitro and animal data
was previously disclosed. Based on promising evidence, we are
pursuing human trials, for which the FDA must give permission.
Following Pre-INDA meeting correspondence in late 2018, we
submitted an INDA to the FDA in November 2019. This process
included presenting the results of in vitro and animal studies,
safety data, a protocol outlining how a potential trial will be
run, how data will be collected, how participant data will be
protected, how IGC-AD1 will be made, who will make it, what is in
it, data on the stability of the formulation, and details on the
Chemistry, Manufacturing, and Controls (CMC). We also agreed a) to
obtain an Informed Consent Form (ICF) from participants that would
be reviewed and approved by an IRB, and b) to follow all rules
required for studying IDCs, including those surrounding
While we cannot guarantee the time frame, taking into account
the upcoming holidays and current restrictions brought on by
COVID-19, we expect to complete the phase 1 study during the first
half of calendar 2021.
IGC operates two lines of business: (i) infrastructure and (ii)
life sciences. The Company is based in Potomac, Maryland, U.S.A.
social media: www.igcinc.us www.igcpharma.com Twitter @IGCIR.
About Alzheimer’s Disease:
Alzheimer’s Disease (AD) is the most common cause of dementia.
It is a progressive disorder that destroys memory and other
important mental functions. AD currently affects more than 5.3
million Americans, about 44 million worldwide, and over 65% of AD
patients are women. It is known as America’s most expensive
disease, with an estimated cost to the U.S. economy of $236
billion. To date, no effective cure has been found.
This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on IGC’s
expectations and are subject to several risks and uncertainties,
certain of which are beyond IGC’s control. For the next several
years, our success is highly correlated primarily with the
successful outcome of our clinical trials and the recovery of the
world and regional economies following the COVID-19 pandemic and
secondarily on the sale of our products and services candidates.
IGC may not be able to complete human trials on our investigational
drug candidates or, once conducted, the results of human trials
testing results may not be favorable or as anticipated. IGC may not
be able to complete human trials on the estimated and expected
timelines for various reasons, including low enrollment of or
inability to enroll qualified patients. Our projections and
investments anticipate stable pricing, which may not hold out over
the next several years, as well as certain regulatory changes,
specifically in states and territories where medical cannabis has
been legalized, and the diseases which we anticipate our products
will target are, become, or remain approved conditions for
treatment or usage with cannabis/cannabinoids. We may not be able
to protect our intellectual property adequately or receive patents.
We may not receive regulatory approval for our products, or trials.
An additional risk factor worth highlighting is that the patent
applications we have licensed may not be granted by the United
States Patent and Trademark Office (“USPTO”), even if the Company
is in full compliance with USPTO requirements. We may not have
adequate resources, including financial resources, to successfully
conduct all requisite clinical trials, to bring products to market,
or to pay applicable maintenance fees over time. We may not be able
to successfully commercialize our products, even if they are
successful and receive regulatory approval. Failure or delay with
respect to any of the factors above could have a material adverse
effect on our business, future results of operations, our stock
price, and our financial condition. Actual results could differ
materially from these forward-looking statements as a result of,
among other factors, competitive conditions in the industries in
which IGC operates, failure to commercialize one or more of the
technologies of IGC, general economic conditions that are less
favorable than expected, the FDA’s general position regarding
hemp-based products, the ongoing COVID-19 pandemic and its effect
on global and regional economies in which IGC participates, and
other factors, many of which are discussed in IGC’s SEC filings.
IGC incorporates by reference the Risk Factors identified in its
Annual Report on Form 10-K filed with the SEC on July 13, 2020,
Quarterly Reports on Form 10-Q filed with the SEC on August 19,
2020 and November 20, 2020 as if fully set forth and restated
herein. In light of these risks and uncertainties, there can be no
assurance that the forward-looking information contained in this
release will in fact occur.
version on businesswire.com: https://www.businesswire.com/news/home/20201123005670/en/
Claudia Grimaldi firstname.lastname@example.org / Phone: 301-983-0998